/production/original_573352236.gif)
Post by brentie on Aug 21, 2013 8:03:43 GMT -5
Biotech Stocks in Investors Focus – VVUS, ARNA, MNKD, MRK, PFE
"While these big companies look to bring non-insulin diabetes drugs to market in the near future, there’s also a smaller company working hard to score commercially with a new insulin product. MannKind (NASDAQ: MNKD ) recently completed late-stage studies for Afrezza, its inhaled insulin, in treating both type 1 and type 2 diabetes.
Results from these two studies were positive, so MannKind should submit the NDA for Afrezza in the next few months. Anything is possible with the FDA’s decision-making process, but the chances seem good that Afrezza will gain approval sometime in 2014.
MannKind Corporation (NASDAQ:MNKD) shares sunk -4.85% to $6.06 in last trading session. Stock traded in range of $5.97 – $6.51."
www.fiscalinsider.com/152585/biotech-stocks-in-investors-focus-vvus-arna-mnkd-mrk-pfe.html
"While these big companies look to bring non-insulin diabetes drugs to market in the near future, there’s also a smaller company working hard to score commercially with a new insulin product. MannKind (NASDAQ: MNKD ) recently completed late-stage studies for Afrezza, its inhaled insulin, in treating both type 1 and type 2 diabetes.
Results from these two studies were positive, so MannKind should submit the NDA for Afrezza in the next few months. Anything is possible with the FDA’s decision-making process, but the chances seem good that Afrezza will gain approval sometime in 2014.
MannKind Corporation (NASDAQ:MNKD) shares sunk -4.85% to $6.06 in last trading session. Stock traded in range of $5.97 – $6.51."
www.fiscalinsider.com/152585/biotech-stocks-in-investors-focus-vvus-arna-mnkd-mrk-pfe.html